Capitolis UK Approved to Operate an Organized Trading Facility (OTF) by the FCA March 31, 2026 Approval unlocks more optimization opportunities and efficiencies for clients and network
ECCEUKCH: The First Year of Activities to Promote European Extra Virgin Olive Oil in the UK and Switzerland Comes to a Close March 31, 2026 The first year of ECCEUKCH – The Excellence of European Olive Growing in the UK and Switzerland, the three-year information and promotion programme dedicated to high-quality European extra virgin olive oil, co-financed by the European Union under Regulation (EU) No 1144/2014, has come to an end. Promoted by the Tuscan Association of Olive Growers OL.MA. [...]
Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets March 31, 2026 Revenues of €1.8 billion (-4% versus PY) driven by solid performance across key therapeutic areas and global markets, partially offset by Ocaliva® withdrawal impact. Adjusted EBITDA2 of €350 million (-18% versus PY) underpinned by streamlined operational efficiencies and operating model evolution. Like-for-like Revenues up 7%, and EBITDA up 20%, adjusted for voluntarily withdrawal of Ocaliva® from US market. Marketing application under EMA review for the use of Jyseleca® in a new indication of axial spondyloarthritis (axSpA), a chronic inflammatory arthritis, to address unmet patient needs, submitted following the reporting period. Following the reporting period, agreement with GSK plc for worldwide exclusive rights to develop, manufacture and commercialise linerixibat; subsequently granted FDA approval for the US market (March 2026).
AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial March 31, 2026 Early biomarker and safety data show encouraging signals with plans to present additional data in 2H 2026 AviadoBio secures strategic investment from The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) through their Treat FTD Fund to support ASPIRE-FTD Trial AviadoBio regains full rights to AVB-101 gene therapy program
TITAN Group Published the 2025 Integrated Annual Report March 27, 2026 Milestone Growth, Bold Acquisitions and a Strategy Built for the Future
Arm Expands Compute Platform to Silicon Products in Historic Company First March 24, 2026 News Highlights Arm extends its platform breadth to include production silicon products for the first time, offering the broadest choice of compute across IP, Arm Compute Subsystems (CSS) and silicon Introducing the first Arm-designed data center CPU, the Arm AGI CPU, for agentic AI infrastructure, delivering more than 2x performance per rack compared with x86 platforms* Developed with lead partner Meta, with other customers and leading ODMs committed for production, the Arm AGI CPU is backed by strong support from the global ecosystem
Trian and General Catalyst Agree to Increase Merger Consideration to $52.00 Per Share in Cash for Janus Henderson Group plc and Have Made the Only Actionable Proposal March 24, 2026 Amended Merger Agreement Represents a $3.00 All-Cash Price Increase; 25% Premium to Unaffected Share Price; Parties Committed to Closing by Mid-2026 Special Committee Determines that Victory Capital’s Revised Unsolicited March 17, 2026 Proposal Is Not Actionable and Is Not in Best Interests of Janus Henderson and Its Shareholders Amended Merger Agreement’s All-Cash Transaction With Trian and General Catalyst Is Superior From an Expected Value and Certainty Perspective and Is the Only Actionable Proposal
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved March 24, 2026 Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In [...]
Recyclable Packaging and Responsible Water Management: Barilla’s Commitment to a More Sustainable Future March 23, 2026 99.8% of the packaging sold is designed to be recyclable. Over 50% of the materials used in Barilla Group’s packaging are recycled, and 71% are paper-based. +45% water recycled and reused in 2024 compared to 2022, and +164% in water-stressed areas.
Lyten to Establish a Lyten Industrial Hub in Poland March 20, 2026 Lyten announces the establishment of its next Lyten Industrial Hub in Gdańsk, Poland. The hub will bring together key manufacturing and digital resources to support energy infrastructure, the development of artificial intelligence, and the defense sector. In February 2026, Lyten announced the creation of the first Lyten Industrial Hub in Sweden, combining battery production operations there with a 1 GW AI data center campus. Lyten plans to complete its feasibility study by the end of 2026 to determine the full development plan